Press releases
- Insulet to Present at the Jefferies Global Healthcare Conference
- Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
- Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
- Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
- Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
- Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
- Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 279.89 |
---|---|
High | 279.89 |
Low | 279.89 |
Bid | 281.93 |
Offer | 283.02 |
Previous close | 279.89 |
Average volume | -- |
---|---|
Shares outstanding | 70.04m |
Free float | 69.80m |
P/E (TTM) | 55.16 |
Market cap | 12.41bn USD |
EPS (TTM) | 3.21 USD |
Data delayed at least 15 minutes, as of Apr 27 2023.
More ▼